You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Interleukin-18 (IL-18)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Early Disease Onset Trial (Puva (psoralin and uva ))

Not yet recruiting
  • Early Disease Onset
  • Puva (psoralin and uva )
  • (no location specified)
Sep 27, 2023

Metastatic Solid Tumor Trial ([18F]AlF-RESCA-IL2 PET scan)

Not yet recruiting
  • Metastatic Solid Tumor
  • [18F]AlF-RESCA-IL2 PET scan
  • (no location specified)
Jul 20, 2022

Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in United States

Active, not recruiting
Has Results
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • +6 more
  • Los Angeles, California
  • +3 more
Nov 16, 2022

Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)

Active, not recruiting
  • Malignant Neoplasm
  • aldesleukin
  • +7 more
  • Los Angeles, California
    University of California at Los Angeles (UCLA )
Dec 1, 2022

NGAL, IL 18 as Predictors of Acute Kidney Injury in Renal

Completed
  • Kidney Transplant; Complications
  • Acute Kidney Injury
    • (no location specified)
    Oct 18, 2021

    Systemic Lupus Erythematosus Trial in Beijing (Telitacicept, Interleukin-2)

    Recruiting
    • Systemic Lupus Erythematosus
    • Beijing, Beijing, China
      Department of Rheumatology and Immunology, Peking University Peo
    Apr 26, 2022

    Non Hodgkin Lymphoma Trial (TMhuCART19-IL18)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • TMhuCART19-IL18
    • (no location specified)
    Aug 2, 2023

    Obesity, Adolescent Trial in Surabaya

    Recruiting
    • Obesity, Adolescent
      • Surabaya, East Java, Indonesia
        RS Bhayangkara Surabaya
      Nov 21, 2023

      Periodontitis Trial (No intervention was applied to the groups the samples will be collected in terms of the diagnosis (

      Not yet recruiting
      • Periodontitis
      • No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)
      • (no location specified)
      Mar 31, 2022

      Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

      Recruiting
      • Neuroblastoma Recurrent
      • Natural killer cell
      • +4 more
      • Hong Kong, Hong Kong
        Hong Kong Children's Hospital
      Feb 22, 2023

      Il-17 and Il-18 in Aggressive Periodontitis

      Completed
      • Aggressive Periodontitis
      • non surgical periodontal therapy
      • Cairo, Egypt
        Faculty of oral and dental medicine,FUE, Cairo,Egypt
      Mar 30, 2022

      Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

      Terminated
      • Neuroblastoma
      • antibody ch14.18
      • +4 more
      • Cologne, Germany
        University of Cologne
      Nov 3, 2022

      High Risk Neuroblastoma Trial in United States (biological, other, drug)

      Completed
      Has Results
      • High Risk Neuroblastoma
      • Aldesleukin
      • +4 more
      • Loma Linda, California
      • +31 more
      Jul 30, 2021

      Gingivitis Trial in Riyadh (Nigella Sativa oil, Chlorhexidine mouthwash)

      Completed
      • Gingivitis
      • Nigella Sativa oil
      • Chlorhexidine mouthwash
      • Riyadh, Saudi Arabia
        Princess Nourah bint Abdulrahman University Dental Clinic
      Sep 25, 2021

      Inflammatory Markers in Chronic Periodontitis Patients

      Completed
      • Aggressive Periodontitis
      • non surgical periodontal therapy
      • Cairo, Egypt
        Future university in Egypt
      Mar 16, 2022

      Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma Trial in Philadelphia (huCART19-IL18)

      Recruiting
      • Chronic Lymphocytic Leukemia
      • Non-hodgkin Lymphoma
      • huCART19-IL18
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      Oct 18, 2021

      Melanoma Trial in Madison (hu14.18-IL2, Radiation Therapy, Nivolumab)

      Suspended
      • Melanoma
      • hu14.18-IL2
      • +3 more
      • Madison, Wisconsin
        University of Wisconsin Carbone Cancer Center
      Jan 3, 2022

      Contribution of Inflammation and Neuronal Integrity Markers in

      Recruiting
      • Conversion Disorder
      • blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)
      • Nîmes, Choisir Une Région, France
        Ismael CONEJERO
      Apr 15, 2022

      Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States

      Recruiting
      • Refractory Acute Myeloid Leukemia
      • +4 more
      • CD371-YSNVZ-IL18 CAR T cells
      • Basking Ridge, New Jersey
      • +6 more
      Aug 29, 2023

      COVID-19, Lymphocytopenia Trial in United Kingdom (Interleukin-7, Placebos)

      Terminated
      • COVID-19
      • Lymphocytopenia
      • Birmingham, United Kingdom
      • +12 more
      Mar 30, 2022

      Hepatitis C Trial (interleukin IL-1beta and interleukin IL-18)

      Unknown status
      • Hepatitis C
      • interleukin IL-1beta and interleukin IL-18
      • (no location specified)
      Jan 24, 2020

      Melanoma (Skin) Trial in Madison (hu14.18-IL2 fusion protein)

      Completed
      • Melanoma (Skin)
      • hu14.18-IL2 fusion protein
      • Madison, Wisconsin
        University of Wisconsin Paul P. Carbone Comprehensive Cancer Cen
      Nov 15, 2019

      Neuroblastoma Trial in Worldwide (ch14.18/CHO, Aldesleukin, Isotretinoin)

      Unknown status
      • Neuroblastoma
      • Vienna, Austria
      • +13 more
      Jul 9, 2020

      Trauma, Brain Trial in Tanta (Amantadine (100mg) as add on therapy., Placebo)

      Completed
      • Trauma, Brain
      • Amantadine (100mg) as add on therapy.
      • Placebo
      • Tanta, Elgarbia, Egypt
        Tanta University Hospital
      Dec 20, 2021

      HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma Trial in Los Angeles

      Withdrawn
      • HLA-A*0201 Positive Cells Present
      • +3 more
      • 18F-FHBG
      • +10 more
      • Los Angeles, California
        UCLA / Jonsson Comprehensive Cancer Center
      Jul 22, 2020